Samtica 250mg Tablet

Samtica 250mg Tablet is a hormonal therapy medication prescribed to treat early-stage prostate cancer in adult men. It is usually taken with a steroid to lower the side effects of other anticancer medicines when taken together. This drug prevents the normal secretion of male sex hormones by inhibiting the actions of the enzyme. Samtica Tablet also relaxes the associated symptoms of prostate cancer, such as difficulty in passing the urine. This tablet can also be a combination drug in chemotherapy to increase its effectiveness. When this medicine is given for an early stage of prostate cancer, it is given with testosterone-lowering treatment. Inform your doctor if you are taking any kind of medications or nutraceuticals. This kind of medicine can react with Samtica 250mg Tablet and may result in some undesirable effects. Before taking this tablet, share with your doctor if you have high blood pressure, heart disease, kidney, or liver problems. It is advised to use reliable methods of birth control and contraceptive pills to avoid pregnancy while under treatment. This tablet should not be given to pregnant and breastfeeding women, as it may pass through the mother and harm the baby. This medicine should not be taken with Ra-223, which is another anticancer medicine to treat prostate cancer.

Like other anticancer medicines, Samtica 250mg Tablet also has some common to severe side effects. These are undesired symptoms observed in the body after taking this tablet. Usually, they disappear with time as the body adjusts to the medicine. These adverse effects don't need special medical attention, but if you observe them continually, talk to your medical expert. Some of them are listed below:

Common side effects:
Vomiting
Diarrhea
Joint pain
Fatigue
Cough
High BP
Constipation
Chest pain
Rashes
Irregular & fast heart rate

Severe side effects:
Swelling
Urinary Tract Infection
Low blood count
Blood in urine
Decreased potassium level in blood

Samtica 250mg Tablet is a prescription-based anticancer drug that should be administered orally. It is advised to take this tablet after consulting your healthcare expert.

Samtica 250mg Tablet is an anticancer medicine which is used to treat prostate cancer. This drug blocks the action of the enzyme CYP17, which signals the production of sex hormones androgen and testosterone in males. That way, it slows down the growth and replication of the cancer cells. Eventually, it inhibits the cancer cells from spreading to other parts of the body and leads to their death.

It is advised not to miss any scheduled dosage of Samtica 250mg Tablet. In case you miss a dose, consult your doctor immediately.

Don't overdose to compensate for the missed one. Contact your doctor or any healthcare provider and seek medical attention immediately.

Samtica 250mg Tablet is usually taken with another medicine, prednisolone to reduce unwanted side effects.

Inform your doctor if you have diabetes or any heart, liver, and kidney problems before taking Samtica 250mg Tablet.

Samtica 250mg Tablet contains lactose and sodium. Share with your physician if you have lactose intolerance.

Use reliable methods of birth control and contraceptive pills to avoid pregnancy while under treatment with Samtica 250mg Tablet.

Your medical professional must monitor your blood sugar & pressure, potassium level, and liver function tests at regular intervals. Taking the Samtica 250mg Tablet can cause fluctuations in their levels.

De Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., & Scher, H. I. (2021). Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine, 364(21),1995-2005.
Fizazi, K., Tran, N., Fein, L., Matsubara, N., Rodriguez-Antolin, A., Alekseev, B. Y. & Chi, K. N. (2024). Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine, 377(4), 352-360.
Ghose, A., Lapitan, P., Apte, V., Ghosh, A., Kandala, A., Basu, S., & Banna, G. L. (2024). Antibody drug conjugates in urological cancers: a review of the current landscape. Current Oncology Reports, 26(6),633-646.
Ryan, C. J., Smith, M. R., Fizazi, K., Saad, F., Mulders, P. F., Sternberg, C. N. & Rathkopf, D. E. (2025). Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. The Lancet Oncology, 16(2),152-160.
Szmulewitz, R. Z., Karrison, T., Stadler, W. M., & Ratain, M. J. (2023). Low-Dose Abiraterone With Food: Rebutting an Editorial. Journal of Clinical Oncology, 36(30),3060-3061.
Szmulewitz, R. Z., Peer, C. J., Ibraheem, A., Martinez, E., Kozloff, M. F., Carthon, B., & Ratain, M. J. (2025). Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer. Journal of Clinical Oncology, 36(14),1389-1395.
Thakur, N., Singh, P., Bagri, A., Srivastava, S., Dwivedi, V., Singh, A. & Dholpuria, S. (2024). Therapy resistance in prostate cancer: mechanism, signaling, and reversal strategies. Exploration of Targeted Anti-tumor Therapy, 5(5),1110.